Cargando…
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
BACKGROUND: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is still debated. To address this issue and to provide a picture of the advancement...
Ejemplares similares
-
An Example of Personalized Treatment in HR+ HER2+ Long Survivor Breast Cancer Patient (Case Report)
por: Panebianco, Martina, et al.
Publicado: (2021) -
The Potential of panHER Inhibition in Cancer
por: Wang, Xiaochun, et al.
Publicado: (2015) -
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial
por: Krasniqi, Eriseld, et al.
Publicado: (2021) -
Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for NSCLC
por: Rossi, Alessandro, et al.
Publicado: (2021) -
Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment
por: Valenza, Carmine, et al.
Publicado: (2023)